Maurizio Rolando

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4780730/publications.pdf

Version: 2024-02-01

49 papers

3,606 citations

212478 28 h-index 252626 46 g-index

49 all docs 49 docs citations

49 times ranked

 $\begin{array}{c} 2753 \\ \text{citing authors} \end{array}$

#	Article	IF	CITATIONS
1	Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. International Journal of Molecular Sciences, 2022, 23, 2434.	1.8	50
2	Special Issue "Managing Dry Eye Disease over Time: An Italian Consensus Conference― Journal of Clinical Medicine, 2022, 11, 2507.	1.0	1
3	Management Strategies for Evaporative Dry Eye Disease and Future Perspective. Current Eye Research, 2022, 47, 813-823.	0.7	9
4	Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. British Journal of Ophthalmology, 2021, 105, 446-453.	2.1	81
5	Updated definition and classification of dry eye disease: Renewed proposals using the nominal group and Delphi techniques. European Journal of Ophthalmology, 2021, 31, 42-48.	0.7	22
6	latrogenic Dry Eye Disease: Dealing with the Conundrum of Post-Cataract Discomfort. A P.I.C.A.S.S.O. Board Narrative Review. Ophthalmology and Therapy, 2021, 10, 211-223.	1.0	13
7	Are there Clinical Ways to Assess Inflammation in Dry Eye Disease?. Ocular Immunology and Inflammation, 2021, 29, 1183-1189.	1.0	9
8	The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders. Survey of Ophthalmology, 2021, 66, 907-925.	1.7	56
9	Defining Dry Eye from a Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 9271.	1.8	118
10	Should We Reconsider the Classification of Patients with Dry Eye Disease?. Ocular Immunology and Inflammation, 2019, 29, 1-3.	1.0	11
11	Reconsidering the central role of mucins in dry eye and ocular surface diseases. Progress in Retinal and Eye Research, 2019, 71, 68-87.	7.3	78
12	Controlled Adverse Environment Chambers in Dry Eye Research. Current Eye Research, 2018, 43, 445-450.	0.7	20
13	Neurotrophic keratopathy. Progress in Retinal and Eye Research, 2018, 66, 107-131.	7.3	250
14	Clinical impact of inflammation in dry eye disease: proceedings of the <scp>ODISSEY</scp> group meeting. Acta Ophthalmologica, 2018, 96, 111-119.	0.6	100
15	The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board. International Ophthalmology, 2018, 38, 875-895.	0.6	21
16	Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocular Surface, 2017, 15, 179-192.	2.2	107
17	The role of systemic and topical fatty acids for dry eye treatment. Progress in Retinal and Eye Research, 2017, 61, 23-34.	7.3	40
18	Safety and Efficacy of Cortisol Phosphate in Hyaluronic Acid Vehicle in the Treatment of Dry Eye in Sjogren Syndrome. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 383-390.	0.6	10

#	Article	IF	Citations
19	Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting. Ocular Surface, 2017, 15, 169-178.	2.2	57
20	Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmologica, 2016, 94, 499-506.	0.6	45
21	Understanding Symptoms and Quality of Life inÂPatients With Dry Eye Syndrome. Ocular Surface, 2016, 14, 365-376.	2.2	86
22	Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. British Journal of Ophthalmology, 2016, 100, 300-306.	2.1	332
23	MGD Diagnosis and Treatment. Current Ophthalmology Reports, 2014, 2, 65-74.	0.5	0
24	Diagnosing the severity of dry eye: a clear and practical algorithm. British Journal of Ophthalmology, 2014, 98, 1168-1176.	2.1	167
25	The Effect of an Artificial Tear Combining Hyaluronic Acid and Tamarind Seeds Polysaccharide in Patients with Moderate Dry Eye Syndrome: A New Treatment for Dry Eye. European Journal of Ophthalmology, 2014, 24, 173-178.	0.7	36
26	Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the OCEAN Group Meeting. Ocular Surface, 2013, 11, 246-258.	2.2	359
27	Towards a dynamic customised therapy for ocular surface dysfunctions. British Journal of Ophthalmology, 2013, 97, 955-960.	2.1	37
28	The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction., 2011, 52, 2050.		470
29	Ophthalmic preservatives: focus on polyquaternium-1. Expert Opinion on Drug Delivery, 2011, 8, 1425-1438.	2.4	25
30	Effects of a New Lipid Tear Substitute in a Mouse Model of Dry Eye. Cornea, 2010, 29, 802-806.	0.9	12
31	Immune response in the conjunctival epithelium of patients with dry eye. Experimental Eye Research, 2010, 91, 524-529.	1.2	66
32	Protecting the Ocular Surface and Improving the Quality of Life of Dry Eye Patients: A Study of the Efficacy of an HP-Guar Containing Ocular Lubricant in a Population of Dry Eye Patients. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 271-278.	0.6	35
33	New Test to Quantify Lipid Layer Behavior in Healthy Subjects and Patients With Keratoconjunctivitis Sicca. Cornea, 2008, 27, 866-870.	0.9	29
34	Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study. BMC Ophthalmology, 2007, 7, 5.	0.6	57
35	Distribution of Conjunctival HLA-DR Expression and the Pathogenesis of Damage in Early Dry Eyes. Cornea, 2005, 24, 951-954.	0.9	88
36	Systemic Linoleic and î³-Linolenic Acid Therapy in Dry Eye Syndrome With an Inflammatory Component. Cornea, 2003, 22, 97-101.	0.9	146

#	Article	IF	Citations
37	The Ocular Surface and Tear Film and Their Dysfunction in Dry Eye Disease. Survey of Ophthalmology, 2001, 45, S203-S210.	1.7	287
38	Three-dimensional optic nerve head algorithm for the detection of glaucomatous damage. Graefe's Archive for Clinical and Experimental Ophthalmology, 2001, 239, 469-473.	1.0	1
39	Quality of vision with presbyopic contact lens correction: subjective and light sensitivity rating. , 2001, 239, 656-663.		3
40	Sj $\tilde{\textbf{A}}$ ¶gren's syndrome as seen by an ophthalmologist. Scandinavian Journal of Rheumatology, 2001, 30, 27-33.	0.6	10
41	Improvement of the ocular surface using hypotonic 0.4% hyaluronic acid drops in keratoconjunctivitis sicca. Eye, 2000, 14, 892-898.	1.1	52
42	Optic disc surface smoothness and visual field indices. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 372-376.	1.0	7
43	A comparative study of computerised visual field testing and optic disc morphometric parameters in the follow-up of primary open angle glaucoma. Eye, 1998, 12, 916-920.	1.1	6
44	Low Spatial-Contrast Sensitivity in Dry Eyes. Cornea, 1998, 17, 376.	0.9	100
45	Efficacy and Safety of 0.3% Carbomer Gel Compared to Placebo in Patients with Moderate-to-Severe Dry Eye Syndrome. Ophthalmology, 1997, 104, 1402-1408.	2.5	35
46	Intraimage reproducibility of measurements in the macular area using a computerized system. International Ophthalmology, 1997, 21, 153-159.	0.6	1
47	Morphometric analysis of the optic disc surface. International Ophthalmology, 1997, 20, 15-20.	0.6	8
48	Ocular Surface Changes Induced by Repeated Impression Cytology. Advances in Experimental Medicine and Biology, 1994, 350, 249-254.	0.8	9
49	Tear Water Evaporation and Eye Surface Diseases. Ophthalmologica, 1985, 190, 147-149.	1.0	44